Objective
In this proof of concept project, we will assess the technical and commercial feasibility of a hybrid microneedle patch for the treatment of nosocomial skin infections caused by drug resistant bacteria. Not only does this device permeate difficult-to-penetrate skin layers to deliver antibiotics locally, it also weakens bacterial defences by raising local temperature to enhance drug effectiveness. In this manner, the need for high dosage systemic drug administration is avoided – reducing occurrence of associated side-effects and perpetuation of antimicrobial resistance. It holds the potential not only to revitalise antibacterials for topical, local treatment of skin infections, but to improve dermatological drug delivery as a platform device. In this project, we will validate the device’s fabrication process for additional commercial scalability and functionality with nanocarrier-drug complexes (for enhanced effectiveness of drug delivery to target site), develop a robust IP strategy and secure initial patents, and conduct extensive market analyses and competitor landscaping. Finally, we will formulate a strong business case, and depending on the results of these activities, establish a company.
Fields of science
Call for proposal
ERC-2020-PoC
See other projects for this call
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotHost institution
17177 Stockholm
Sweden
Beneficiaries (2)
17177 Stockholm
171 65 Solna
